Latest From NantWorks LLC
Celgene settles Abraxane patent litigation and inter partes review with Teva's Actavis, allowing a generic to enter the market on March 31, 2022 – about four years before the drug's key patents expire.
A review of biopharma start-up deal-making and financing activity from July through September 2017, based on data from Strategic Transactions, showed that fundraising declined 18% from the previous quarter, however the number of acquisitions doubled to eight.
The Vice President’s cancer “moonshot” is a great opportunity for biopharma companies to engage in a process that should remind policymakers and the public of the promise of biomedical innovation at a time when the industry’s pricing and financial engineering activities are under scrutiny on Capitol Hill. The selection of the “blue ribbon” panel puts those two images in stark contrast.
Start-ups raised $2.41 billion in Q4 2015. Biopharma companies penned 29 alliances; seven acquisitions were signed in the biopharma and diagnostics industries.
- In Vitro Diagnostics
- Monitoring Equipment & Devices
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- NantWorks LLC
- Senior Management
- Patrick Soon-Shiong, MD, Chmn.
- Contact Info
Phone: (310) 883-1300
9920 Jefferson Blvd.
Culver City, CA 90232
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.